CLDN6 inhibits breast cancer growth and metastasis through SREBP1-mediated RAS palmitoylation
Our findings provide compelling evidence that CLDN6 suppresses the palmitic acid-induced RAS palmitoylation through the MAGI2/KLF5/SREBP1 axis, thereby impeding BC malignant progression. These results propose a new insight that monitoring CLDN6 expression alongside targeting inhibition of palmitic acid-mediated palmitoylation could be a viable strategy for treating oncogenic RAS-driven BC.
Authors
- Mingzi Zhang (ORCID: https://orcid.org/0000-0002-0118-1160)
- Chengshi Quan (ORCID: https://orcid.org/0000-0001-9307-5279)
- Jin Qiu (ORCID: https://orcid.org/0009-0001-1528-2122)
- Huinan Qu
- Da Qi (ORCID: https://orcid.org/0000-0001-6079-9764)
- Minghao Sun (ORCID: https://orcid.org/0000-0002-1657-0740)
- Yuan Dong
Institutions
- University of Southern California (US)
- Jilin University (CN)
- Jilin Medical University (CN)
Publication Details
- Journal
- Cellular & Molecular Biology Letters
- Published
- 2024-08-21
- DOI
- https://doi.org/10.1186/s11658-024-00629-y
- Citations
- 17
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 7.12
Funders
- National Natural Science Foundation of China
- People's Government of Jilin Province
- Jilin University
- Department of Science and Technology of Jilin Province